Research Reports

Key takeaways

Eli Wallace, Ph.D. resigned as Board member and Class III director on April 20, 2026, succeeded by Pedro J. Beltran, Ph.D. as director, President, and CEO.

Consulting Agreement with Dr. Wallace effective retroactively April 21, 2026, for 12 months unless terminated earlier.

Dr. Wallace's sole compensation is continued vesting of outstanding equity awards, subject to service through vesting dates.

Post-termination, vested stock options exercisable for up to 2 years or original expiration, whichever earlier.

Dr. Wallace entitled to Tier 1 officer severance benefits under Executive Severance Plan and Separation Agreement dated April 27, 2026.

Full analysis

The disclosure details the transition of leadership at BridgeBio Oncology Therapeutics Inc., where Eli Wallace, Ph.D. stepped down from his roles as Class III director, President, and CEO effective April 20, 2026, with Pedro J. Beltran, Ph.D. assuming those positions. To retain Dr. Wallace's expertise, the Company entered a consulting agreement on April 27, 2026, effective retroactively from April 21, 2026, for up to 12 months. Compensation under this arrangement is limited to continued vesting of his pre-existing equity awards, contingent on providing advisory services on R&D programs through vesting dates. Vested options receive an extended exercise period post-termination. Additionally, Dr. Wallace receives severance benefits as a Tier 1 officer per the Executive Severance Plan from August 2025 and a related separation agreement, signaling a structured exit without cause. This arrangement maintains continuity in R&D guidance while formalizing the CEO transition previously reported.

BBOT · BridgeBio Oncology Therapeutics Inc.

Summary

Key takeaways

Full analysis